NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free EYEN Stock Alerts $0.52 -0.05 (-8.83%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.51▼$0.5750-Day Range$0.52▼$2.3752-Week Range$0.50▼$5.85Volume1.15 million shsAverage Volume1.52 million shsMarket Capitalization$24.48 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Eyenovia alerts: Email Address Eyenovia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,836.1% Upside$10.00 Price TargetShort InterestBearish11.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$176,433 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.89) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector847th out of 910 stocksPharmaceutical Preparations Industry400th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.01% of the outstanding shares of Eyenovia have been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Eyenovia has recently increased by 46.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYEN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Eyenovia this week, compared to 2 articles on an average week.Search InterestOnly 26 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $176,433.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($0.89) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Eyenovia Stock (NASDAQ:EYEN)Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Read More EYEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYEN Stock News HeadlinesMarch 30, 2024 | insidertrades.comStuart M. Grant Acquires 100,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) StockApril 17, 2024 | msn.comEyenovia (EYEN) Price Target Decreased by 24.29% to 7.21April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 10, 2024 | investing.comEyenovia explores strategic alternatives amid new product developmentsApril 8, 2024 | marketwatch.comEyenovia Shares Fall More Than 14% After Company Says It Is Exploring SaleApril 8, 2024 | marketwatch.comEyenovia Explores Options, Including Potential SaleApril 8, 2024 | globenewswire.comEyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial OpportunitiesApril 5, 2024 | reuters.comEyenovia IncApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 4, 2024 | msn.comLenz Therapeutics’ Eye Drop Helps Improve Vision in Late-Stage StudyApril 3, 2024 | globenewswire.comEyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare MeetingsMarch 20, 2024 | seekingalpha.comEyenovia, Inc. (EYEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finanznachrichten.deEyenovia, Inc.: Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | markets.businessinsider.comEyenovia’s Strategic Commercial Synergy and Growth Potential Reinforce Buy RatingMarch 19, 2024 | finance.yahoo.comEyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Eyenovia Inc Earnings CallMarch 18, 2024 | benzinga.comRecap: Eyenovia Q4 EarningsMarch 18, 2024 | investorplace.comEYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023March 18, 2024 | markets.businessinsider.comEyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comEyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 17, 2024 | msn.comEyenovia Q4 2023 Earnings PreviewMarch 13, 2024 | globenewswire.comNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsMarch 11, 2024 | markets.businessinsider.comEyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18thMarch 11, 2024 | globenewswire.comEyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18thMarch 6, 2024 | markets.businessinsider.comEyenovia, Formosa Gets FDA Approval For Clobetasol Propionate Ophthalmic Eye DropsMarch 6, 2024 | markets.businessinsider.comEyenovia’s Strategic Expansion: Dual Product Offering Enhances Market PositionMarch 6, 2024 | msn.comEyenovia falls despite FDA nod for pain therapySee More Headlines Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/22/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EYEN CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,836.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,260,000.00 Net MarginsN/A Pretax Margin-719,857.44% Return on Equity-213.33% Return on Assets-89.16% Debt Debt-to-Equity Ratio1.00 Current Ratio2.17 Quick Ratio2.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book2.58Miscellaneous Outstanding Shares47,390,000Free Float43,690,000Market Cap$24.48 million OptionableOptionable Beta1.65 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Tsontcho Ianchulev M.D. (Age 49)M.P.H., MPH, Co-Founder & Executive Chairman Comp: $920.87kMr. Michael M. Rowe (Age 62)CEO & Director Comp: $750.01kMr. John P. Gandolfo CPA (Age 63)CFO & Secretary Comp: $598.39kMr. Bren Kern (Age 42)COO & Corporate VP Alexander LoboInvestor ContactKey CompetitorsAcurx PharmaceuticalsNASDAQ:ACXPAileron TherapeuticsNASDAQ:ALRNSol-Gel TechnologiesNASDAQ:SLGLForte BiosciencesNASDAQ:FBRXEnlivex TherapeuticsNASDAQ:ENLVView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 70,000 shares on 4/22/2024Ownership: 0.148%Stuart M GrantBought 100,000 shares on 3/28/2024Total: $98,000.00 ($0.98/share)Stuart M GrantBought 50,000 shares on 3/19/2024Total: $61,500.00 ($1.23/share)Leo Wealth LLCBought 16,112 shares on 3/14/2024Ownership: 0.037%Stuart M GrantBought 10,717 shares on 3/8/2024Total: $16,932.86 ($1.58/share)View All Insider TransactionsView All Institutional Transactions EYEN Stock Analysis - Frequently Asked Questions Should I buy or sell Eyenovia stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYEN shares. View EYEN analyst ratings or view top-rated stocks. What is Eyenovia's stock price target for 2024? 3 analysts have issued 12-month target prices for Eyenovia's shares. Their EYEN share price targets range from $8.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,836.1% from the stock's current price. View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts. How have EYEN shares performed in 2024? Eyenovia's stock was trading at $2.08 at the start of the year. Since then, EYEN shares have decreased by 75.2% and is now trading at $0.5165. View the best growth stocks for 2024 here. Are investors shorting Eyenovia? Eyenovia saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 46.2% from the March 15th total of 3,570,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 5.1 days. View Eyenovia's Short Interest. When is Eyenovia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EYEN earnings forecast. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) announced its earnings results on Monday, March, 18th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). During the same period last year, the business posted ($0.17) EPS. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS). When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. Who are Eyenovia's major shareholders? Eyenovia's stock is owned by a number of institutional and retail investors. Top institutional investors include PFG Investments LLC (0.15%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View institutional ownership trends. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EYEN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
